Increased Levels and Activity of Matrix Metalloproteinase-9 in Obstructive Sleep Apnea Syndrome

Matrix metalloproteinases (MMPs) are involved in the pathogenesis of cardiovascular diseases. We examined serum levels of MMP-9 and its inhibitor, tissue inhibitor of metalloproteinase-1 (TIMP-1), activity of MMP-9, and the effect of nasal continuous positive airway pressure (nCPAP) in patients with...

Full description

Saved in:
Bibliographic Details
Published in:American journal of respiratory and critical care medicine 2004-12, Vol.170 (12), p.1354-1359
Main Authors: Tazaki, Toshiyuki, Minoguchi, Kenji, Yokoe, Takuya, Samson, Karen Thursday R, Minoguchi, Hideko, Tanaka, Akihiko, Watanabe, Yoshio, Adachi, Mitsuru
Format: Article
Language:English
Subjects:
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Atherosclerosis
Biological and medical sciences
Blood. Blood coagulation. Reticuloendothelial system
Cardiovascular disease
Chronic obstructive pulmonary disease, asthma
Cytokines
Humans
Hypoxia
Intensive care medicine
Male
Matrix Metalloproteinase 9 - metabolism
Medical sciences
Middle Aged
Mortality
Pharmacology. Drug treatments
Pneumology
Severity of Illness Index
Sleep apnea
Sleep Apnea Syndromes - enzymology
Tissue Inhibitor of Metalloproteinase-1 - metabolism
Tumor necrosis factor-TNF
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Matrix metalloproteinases (MMPs) are involved in the pathogenesis of cardiovascular diseases. We examined serum levels of MMP-9 and its inhibitor, tissue inhibitor of metalloproteinase-1 (TIMP-1), activity of MMP-9, and the effect of nasal continuous positive airway pressure (nCPAP) in patients with obstructive sleep apnea syndrome (OSAS). After polysomnography, venous blood was collected at 5:00 A.M. from 44 patients with OSAS and 18 control subjects who were obese, and serum levels of MMP-9, TIMP-1, and enzymatic activity of MMP-9 were measured. In addition, the effects of 1 month of treatment with nCPAP were studied in patients with moderate to severe OSAS. Although serum levels of MMP-9 (p < 0.03) and MMP-9 activity (p < 0.01) were higher in patients with OSAS than in control subjects who were obese, TIMP-1 levels did not differ significantly. In patients with OSAS, the severity of OSAS was the primary factor influencing levels (p < 0.01) and activity (p < 0.01) of MMP-9. nCPAP significantly decreased serum levels (p < 0.01) and activity (p < 0.001) of MMP-9 but did not affect TIMP-1 levels. Therefore, OSAS may increase risks of cardiovascular morbidity, and nCPAP might be useful for decreasing these risks.
ISSN:1073-449X
1535-4970
DOI:10.1164/rccm.200402-193OC